Voss Capital LP Raises Position in Cellebrite DI Ltd. $CLBT

Voss Capital LP boosted its stake in shares of Cellebrite DI Ltd. (NASDAQ:CLBT) by 18.9% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 8,050,000 shares of the company’s stock after purchasing an additional 1,277,300 shares during the period. Cellebrite DI comprises 7.0% of Voss Capital LP’s portfolio, making the stock its 3rd largest holding. Voss Capital LP owned about 3.36% of Cellebrite DI worth $145,142,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Invesco Ltd. increased its holdings in Cellebrite DI by 58.6% during the third quarter. Invesco Ltd. now owns 5,560,196 shares of the company’s stock valued at $103,030,000 after buying an additional 2,054,644 shares during the last quarter. Pertento Partners LLP increased its holdings in Cellebrite DI by 57.8% during the third quarter. Pertento Partners LLP now owns 4,648,215 shares of the company’s stock valued at $86,131,000 after buying an additional 1,702,574 shares during the last quarter. Cooper Creek Partners Management LLC purchased a new stake in Cellebrite DI during the third quarter valued at approximately $55,999,000. Handelsbanken Fonder AB increased its holdings in Cellebrite DI by 18.4% during the third quarter. Handelsbanken Fonder AB now owns 2,900,000 shares of the company’s stock valued at $53,737,000 after buying an additional 450,000 shares during the last quarter. Finally, Granahan Investment Management LLC increased its holdings in Cellebrite DI by 1,108.5% during the third quarter. Granahan Investment Management LLC now owns 2,629,299 shares of the company’s stock valued at $48,721,000 after buying an additional 2,411,726 shares during the last quarter. Institutional investors own 45.88% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have commented on CLBT. Needham & Company LLC reduced their target price on shares of Cellebrite DI from $18.00 to $15.00 and set a “buy” rating for the company in a report on Friday, May 15th. DA Davidson began coverage on shares of Cellebrite DI in a report on Wednesday, May 27th. They set a “buy” rating and a $20.00 target price for the company. Wall Street Zen raised shares of Cellebrite DI from a “sell” rating to a “hold” rating in a report on Sunday, March 15th. Finally, Weiss Ratings raised shares of Cellebrite DI from a “sell (d+)” rating to a “hold (c-)” rating in a report on Monday, May 18th. Five research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $21.40.

Insider Activity

In other news, CRO Marcus Jewell sold 12,658 shares of the stock in a transaction on Monday, May 18th. The shares were sold at an average price of $12.77, for a total value of $161,642.66. Following the completion of the sale, the executive directly owned 440,101 shares of the company’s stock, valued at $5,620,089.77. This represents a 2.80% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders have sold 13,269 shares of company stock valued at $169,592 over the last three months. Corporate insiders own 5.70% of the company’s stock.

Cellebrite DI Price Performance

Shares of NASDAQ CLBT opened at $12.84 on Friday. The firm has a fifty day moving average price of $13.23 and a 200-day moving average price of $15.05. The stock has a market cap of $3.20 billion, a PE ratio of 45.86, a price-to-earnings-growth ratio of 1.59 and a beta of 1.17. Cellebrite DI Ltd. has a 1 year low of $11.02 and a 1 year high of $19.98.

About Cellebrite DI

Cellebrite DI is a global provider of digital intelligence and forensics solutions that enable law enforcement agencies, government bodies and enterprises to extract, analyze and act on data from mobile devices, cloud services and digital sources. The company’s technology is designed to accelerate investigations, support evidence-based decision-making and enhance security operations by delivering actionable intelligence in a secure, scalable platform.

The company’s flagship offerings include the Universal Forensic Extraction Device (UFED) series for data acquisition and decoding, Physical Analyzer for advanced data parsing and visualization, and Pathfinder for case-driven investigation workflows.